Mindset Pharma Inc. announced that it has filed two international patent applications under the Patent Coorperation Treaty ("PCT") for the protection of certain of Mindset's non-hallucinogenic novel non-tryptamine compounds known as "Family 6." The filings are based on pre-clinical studies and provide Mindset with preliminary freedom to operate for all claimed drug candidates from Family 6. The pre-clinical study results underpinning the candidates identified in these patent applications are highly promising. Work performed on these novel non-tryptamine candidates, which included in-vitro screening, and ADME (absorption, distribution, metabolism, and excretion), along with in vivo studies, indicates 5-HT2A serotonin receptor activation without the cardinal in vivo signs of a hallucinogenic effect. While some Family 6 compounds are functionally more potent than psilocybin and 5-MeO-DMT as 5-HT2A agonists, these drug candidates elicited only a modest or no head muscle response, suggesting a non-hallucinogenic effect profile.
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |